Table 1 The detailed information of each cohort in this study
From: Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations
Characteristic | Zehir Cohort N = 1567 | Samstein Cohort N = 350 | OAK/POPLAR cohort N = 569 |
|---|---|---|---|
Age (median) |  | 67 (range, 31–90) | 63 (range, 33–82) |
 < 65 | NA | 143 (40.9%) | 322 (56.6%) |
 ≥ 65 | NA | 207 (59.1%) | 247 (43.4%) |
Gender | Â | Â | Â |
 Female | 886 (56.5%) | 180 (51.4%) | 215 (37.8%) |
 Male | 681(43.5%) | 170 (48.6%) | 354 (62.2%) |
Smoking status | Â | Â | Â |
 Prev/Current | 972 (62.0%) | NA | 458 (80.5%) |
 Never | 334 (21.3%) | NA | 111 (19.5%) |
 Unknown | 261 (16.7%) |  |  |
Histology | Â | Â | Â |
 LUAD | 1268 (80.9%) | 271 (77.4%) |  |
 Non-squamous |  |  | 408 (71.7%) |
 LUSC | 123 (8.1%) | 45 (12.9%) | 161 (28.3%) |
 Others | 176 (11.2%) | 34 (9.7%) |  |
Treatment type | Â | Â | Â |
 PD1/PD-L1 | NA | 329 (94.0%) | 569 (100.0%) |
 Combination | NA | 21 (6.0%) |  |
PD-L1 expression | Â | Â | Â |
TC0 and IC0 | NA | NA | 180 (31.6%) |
TC1/2/3or IC1/2/3 | NA | NA | 241 (42.4%) |
Unknown | Â | Â | 4 (0.7%) |
TMB | 1567 (100.0%) | 350 (100%) | NA |
bTMB | NA | NA | 429 (75.4%) |
Gene mutation | Â | Â | Â |
 NTRK1 MT | 55 (3.5%) | 13 (3.7%) | 8 (1.4%) |
 NTRK2 MT | 23 (1.5%) | 9 (2.6%) | 14 (2.5%) |
 NTRK3 MT | 79 (5.0%) | 20 (5.7%) | 40 (7.0%) |
 NTRK MT | 148 (9.4%) | 38 (10.9%) | 58 (10.2%) |
 NTRK WT | 1419 (90.6%) | 312 (89.1%) | 511 (89.8%) |
Overall Survival | 1443 (92.1%) | 350 (100.0%) | 569 (100.0%) |